$1.52 Billion is the total value of NEA Management Company, LLC's 35 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 26.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | TESARO INC | $355,056,000 | -31.8% | 8,854,255 | 0.0% | 23.39% | -13.9% | |
| ARDX | ARDELYX INC | $177,882,000 | +8.2% | 10,294,096 | 0.0% | 11.72% | +36.5% | |
| GRPN | GROUPON INC | $144,004,000 | -35.2% | 44,172,953 | 0.0% | 9.49% | -18.2% | |
| SUPN | SUPERNUS PHARMACEUTICALS INC | $107,207,000 | -17.4% | 7,641,250 | 0.0% | 7.06% | +4.3% | |
| CLVS | CLOVIS ONCOLOGY INC | $104,824,000 | +4.6% | 1,139,890 | 0.0% | 6.91% | +32.0% | |
| DERM | DERMIRA INC | $81,845,000 | +33.0% | 3,506,649 | 0.0% | 5.39% | +67.8% | |
| OPWR | OPOWER INC | $80,166,000 | -22.6% | 8,997,290 | 0.0% | 5.28% | -2.3% | |
| EPZM | EPIZYME INC | $66,226,000 | -46.4% | 5,149,740 | 0.0% | 4.36% | -32.4% | |
| TRVN | TREVENA INC | $49,801,000 | +65.3% | 4,811,691 | 0.0% | 3.28% | +108.6% | |
| GLYC | GLYCOMIMETICS INC | $48,021,000 | -29.6% | 8,575,135 | 0.0% | 3.16% | -11.1% | |
| NVRO | NEVRO CORP | $46,085,000 | -13.7% | 993,428 | 0.0% | 3.04% | +8.9% | |
| LOXO | LOXO ONCOLOGY INC | $31,328,000 | -3.0% | 1,792,207 | 0.0% | 2.06% | +22.3% | |
| HIVE | AEROHIVE NETWORKS INC | $27,995,000 | -14.3% | 4,681,455 | 0.0% | 1.84% | +8.1% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $25,586,000 | +33.4% | 2,382,286 | 0.0% | 1.69% | +68.4% | |
| TRIV | TRIVASCULAR TECHNOLOGIES INC | $19,726,000 | -6.5% | 3,945,191 | 0.0% | 1.30% | +18.0% | |
| TCON | TRACON PHARMACEUTICALS INC | $18,462,000 | -13.8% | 1,889,652 | 0.0% | 1.22% | +8.8% | |
| CRCM | CARE COM INC | $16,761,000 | -13.2% | 3,260,989 | 0.0% | 1.10% | +9.5% | |
| MM | MILLENNIAL MEDIA INC | $14,393,000 | +8.0% | 8,224,752 | 0.0% | 0.95% | +36.2% | |
| EXEL | EXELIXIS INC | $12,381,000 | +49.2% | 2,207,000 | 0.0% | 0.82% | +88.5% | |
| ZSAN | ZOSANO PHARMA CORP | $8,548,000 | -45.4% | 2,158,543 | 0.0% | 0.56% | -31.1% | |
| CSBR | New | CHAMPIONS ONCOLOGY INC | $8,359,000 | – | 1,562,500 | +100.0% | 0.55% | – |
| CVT | CVENT INC | $8,217,000 | +30.6% | 244,106 | 0.0% | 0.54% | +64.4% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $8,011,000 | -23.1% | 3,243,150 | 0.0% | 0.53% | -2.9% | |
| OREX | OREXIGEN THERAPEUTICS INC | $7,826,000 | -57.4% | 3,709,000 | 0.0% | 0.52% | -46.2% | |
| ABIO | New | ARCA BIOPHARMA INC | $7,243,000 | – | 1,460,209 | +100.0% | 0.48% | – |
| AUPH | AURINIA PHARMACEUTICALS INC | $7,233,000 | -6.0% | 2,546,843 | 0.0% | 0.48% | +18.7% | |
| ZHNE | ZHONE TECHNOLOGIES INC | $6,550,000 | -38.8% | 4,781,290 | 0.0% | 0.43% | -22.7% | |
| ROKA | ROKA BIOSCIENCE INC | $6,280,000 | -25.0% | 3,220,433 | 0.0% | 0.41% | -5.3% | |
| ECOM | CHANNELADVISOR CORP | $5,534,000 | -16.8% | 556,692 | 0.0% | 0.36% | +5.2% | |
| ARQL | ARQULE INC | $4,713,000 | +16.9% | 2,520,316 | 0.0% | 0.31% | +47.4% | |
| SNSS | New | SUNESIS PHARMACEUTICALS INC | $4,609,000 | – | 5,689,644 | +100.0% | 0.30% | – |
| CBIO | New | CATALYST BIOSCIENCES INC | $3,040,000 | – | 652,380 | +100.0% | 0.20% | – |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $2,375,000 | -47.0% | 125,004 | -28.1% | 0.16% | -33.3% |
| AGRX | AGILE THERAPEUTICS INC | $900,000 | -21.5% | 133,488 | 0.0% | 0.06% | -1.7% | |
| AKTX | New | AKARI THERAPEUTICS PLCadr | $645,000 | – | 26,894 | +100.0% | 0.04% | – |
| ABIO | Exit | ARCA BIOPHARMA INC | $0 | – | -10,221,465 | -100.0% | -0.61% | – |
| TRGT | Exit | TARGACEPT INC | $0 | – | -4,566,666 | -100.0% | -0.66% | – |
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -4,659,333 | -100.0% | -0.73% | – |
| VTAE | Exit | VITAE PHARMACEUTICALS INC | $0 | – | -2,613,199 | -100.0% | -1.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.